Metabolic & GLP
Appetite Regulation Studies
Quantity
Ships from the United States with tracking · free shipping over $200
Certificates of analysis
Each certificate covers one production run, and reports on that batch alone. Open any of them to read the laboratory report exactly as the third-party lab issued it.
Authenticity
Scan the code on the label to pull up every published certificate for that compound — the same reports the third-party laboratory issued, batch by batch. Traceable from the laboratory that tested it to your bench.
Verify a batch →Independently tested
Purity is quantified by reverse-phase HPLC and identity confirmed by mass spectrometry, by an outside laboratory rather than in-house.
A certificate for your lot
The report that ships with your order describes the batch you received — not the product line, and not a representative sample.
COA-backed replacement
If material does not match the certificate issued for its lot, we replace it or refund it. Send us the lot number and we will trace it.
Tracked dispatch
Tracking is issued when the label is created, so the shipment is traceable from the moment it leaves us.
About this compound
C187H291N45O59
GLP-1 S is a selective GLP-1 receptor agonist whose sequence is roughly 94% identical to native GLP-1. The single substitution that accounts for most of the difference sits at the position where DPP-4 would normally cleave the peptide, which is what extends its duration. Research examines receptor selectivity and appetite-signaling endpoints.
Full specification
How it works
The pathways GLP-1 S acts on, and what each one does. Signalling described from preclinical models.
GLP-1 Receptor Agonism
Selective agonism at the GLP-1 receptor, with a sequence roughly 94% identical to the native hormone. Selectivity is the point — it engages one receptor rather than the two or three its newer relatives do.
Central Appetite Regulation
GLP-1 receptors in the hypothalamus and brainstem are the population associated with satiety signalling, which is where appetite endpoints in this literature are measured.
Extended Half-Life Design
The single substitution that accounts for most of the divergence from native GLP-1 sits exactly where DPP-4 would cleave it. Blocking that site is what turns a minutes-long half-life into a useful one.
Uses & applications
The main areas under study, and the study-reported figures behind them.
Body-weight endpoints dominate this literature, measured against placebo and against other agonists in the same class.
Wilding et al. 2021
HbA1c is the primary endpoint, with receptor selectivity the variable distinguishing this compound from dual and triple agonists.
Marso et al. 2016
Outcome trials in this class measure cardiovascular events over years rather than surrogate markers over weeks.
SUSTAIN-6, 2016
Central receptor populations in the hypothalamus and brainstem are studied for satiety signalling rather than peripheral effects.
Davies et al. 2021
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Molecular structure
The verified reference values for this compound.
No 3D structure published
This compound is a long, flexible chain. Any single three-dimensional arrangement would be one of an enormous number it can adopt, so we do not show one. The sequence and the reference values beside this are the reliable description.
C187H291N45O59
Third-party verified
Every batch of GLP-1 S is sent to an accredited independent laboratory before it ships. Here is what we screen for.
Quantifies purity and reports it on the lot certificate
Verifies the exact molecular identity
Lead, arsenic, cadmium & mercury
Bacterial endotoxin levels
No microbial contamination
Actual peptide mass per vial verified
FAQ
GLP-1 S is a selective GLP-1 receptor agonist whose sequence is roughly 94% identical to native GLP-1. The single substitution that accounts for most of the difference sits at the position where DPP-4 would normally cleave the peptide, which is what extends its duration. Research examines receptor selectivity and appetite-signaling endpoints.
Published research on GLP-1 S concentrates on Obesity & Weight Management, Type 2 Diabetes & Glycemic Control, Cardiovascular Outcomes and Appetite & Reward Circuitry. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 3 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes GLP-1 S acting across GLP-1 Receptor Agonism, Central Appetite Regulation and Extended Half-Life Design, reported respectively as GLP-1R, CNS and PK. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
GLP-1 S has a molecular formula of C187H291N45O59 and an average mass of 4113.58 g/mol. It is indexed under CAS 910463-68-2. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. GLP-1 S is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. GLP-1 S is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed and peer-reviewed journals — not Routine Peptides claims.
For research use only
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
